Evidence map›Paper›PMID 26611102›Full record

ReviewNeuromolecular medicine2016

Does PGC1α/FNDC5/BDNF Elicit the Beneficial Effects of Exercise on Neurodegenerative Disorders?

Mohammad Jodeiri Farshbaf, Kamran Ghaedi, Timothy L Megraw, Jennifer Curtiss, Mahsa Shirani Faradonbeh, Pooneh Vaziri, Mohammad Hossein Nasr-Esfahani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neuromolecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 3 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Mohammad Jodeiri FarshbafDepartment of Cellular Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Royan Street, Salman Street, Khorasgan, Isfahan, 8165131378, Iran.
Kamran GhaediDepartment of Cellular Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Royan Street, Salman Street, Khorasgan, Isfahan, 8165131378, Iran. kamranghaedi@royaninstitute.org.
Timothy L MegrawDepartment of Biomedical Sciences, Florida State University College of Medicine, West Call Street, Tallahassee, FL, 32306-4300, USA. timothy.megraw@med.fsu.edu.
Jennifer CurtissDepartment of Biology, New Mexico State University, Las Cruces, NM, USA.
Mahsa Shirani FaradonbehDepartment of Biology, School of Sciences, University of Isfahan, Hezarjerib Street, Azadi Square, Isfahan, 8174673441, Iran.
Pooneh VaziriDepartment of Biology, New Mexico State University, Las Cruces, NM, USA.
Mohammad Hossein Nasr-EsfahaniDepartment of Cellular Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Royan Street, Salman Street, Khorasgan, Isfahan, 8165131378, Iran. mh_nasr@royaninstitute.org.
New Mexico State University · USAcademic Center for Education, Culture and Research · IRFlorida State University · USRoyan Institute · IRUniversity of Isfahan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative disorders such as Alzheimer's, Parkinson's and Huntington's diseases have high prevalence among the elderly. Many strategies have been established to alleviate the symptoms experienced by affected individuals. Recent studies have shown that exercise helps patients with neurological disorders to regain lost physical abilities. PGC1α/FNDC5/BDNF has emerged recently as a critical pathway for neuroprotection. PGC1α is a highly conserved co-activator of transcription factors that preserves and protects neurons against destruction. PGC1α regulates FNDC5 and its processed and secreted peptide Irisin, which has been proposed to play a critical role in energy expenditure and to promote neural differentiation of mouse embryonic stem cells. FNDC5 may also increase the expression of the neurotrophic factor BDNF, a neuroprotective agent, in the hippocampus. BDNF is secreted from hippocampus, amygdala, cerebral cortex and hypothalamus neurons and initiates intracellular signaling pathways through TrkB receptors. These pathways have positive feedback on CREB activities and lead to enhancement in PGC1α expression in neurons. Therefore, FNDC5 could behave as a key regulator in neuronal survival and development. This review presents recent findings on the PGC1α/FNDC5/BDNF pathway and its role in neuroprotection, and discusses the controversial promise of irisin as a mediator of the positive benefits of exercise.

Indexed as

AnimalsBrain-Derived Neurotrophic FactorCyclic AMP Response Element-Binding ProteinEnergy MetabolismExerciseExercise TherapyFeedback, PhysiologicalFibronectinsHumansMiceMitochondriaModels, NeurologicalNerve Tissue ProteinsNeurodegenerative DiseasesNeurogenesisNeuronsBDNF protein, humanBrain-Derived Neurotrophic FactorCREB1 protein, humanCreb1 protein, mouseCyclic AMP Response Element-Binding ProteinFibronectinsFNDC5 protein, humanFNDC5 protein, mouseNerve Tissue ProteinsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPARGC1A protein, humanPpargc1a protein, mouseBDNFFNDC5IrisinNeurodegenerative diseasesNeuroprotectionPGC1α

Identifiers

PMID26611102
OpenAlexW2342501741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.